Brian Bresnahan

Assistant Professor (Adjunct)

Department of Pharmacy, PORPP Faculty

Email: bres@uw.edu

In November 2007, Brian W. Bresnahan joined the Faculty of the University of Washington, Department of Radiology, in Seattle, WA, as a Research Assistant Professor in the Health Services Research section. Dr. Bresnahan, a health economist, also supports the Harborview Medical Center, Department of Radiology through collaboration on economic evaluations, research projects, and quality improvement initiatives.

Most recently, from 2005-2007, Brian was working as a Senior Post-Doctoral Fellow sponsored by Eli Lilly & Company, in the Pharmaceutical Outcomes Research & Policy Program of the Department of Pharmacy at the University of Washington.

Previously, for seven years, he worked as a health economist in the pharmaceutical and bio-technology industry for Johnson & Johnson and Genentech. He has worked in multiple disease areas, including: asthma, bipolar disorder and mental health, cancer-related anemia, dermatologic conditions, and diseases of the central nervous system.

Prior to this, he worked for Westat, Inc., a survey research firm, as a programmer and analyst on the Medical Expenditures Panel Survey (MEPS). Before this, he was a Visiting Professor at Louisiana State University and an Instructor at the University of Georgia, where he received his Ph.D. in Economics. He received his B.S. from Mount Saint Mary’s College, in Emmitsburg, Maryland.

Dr. Bresnahan’s research interests include health outcomes research, health technology assessment, risk-benefit assessment, cost-effectiveness analysis, and health preference evaluation. His current research involves an economic evaluation of a carpal tunnel syndrome study and assessing how payers define and evaluate medical product value in their decision-making processes. He is also working with researchers in the UW Department of Pharmacy on a measles vaccination innovation project funded by the Bill and Melinda Gates Foundation, and is conducting a program evaluation with Premera Blue Cross assessing pharmacy and medical claims for a higher-risk polypharmacy sub-population.